Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.57 |
| ▸ | QPCT | Q16769 | 3/20 | 0.57 |
| ▸ | PRKCA | P17252 | 5/20 | 0.52 |
| ▸ | PRKCB | P05771 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127716 | 0.90 | GSK3B (0.64) | GSK3BQPCTPRKCAPRKCBKDR | |
| SCHEMBL2955502 | 0.83 | PRKCA (0.54) | GSK3BPRKCAPRKCBCCNE2CDK4 | |
| SCHEMBL6069262 | 0.83 | GSK3B (0.71) | GSK3BQPCTPRKCAPRKCBCCNE2 | |
| SCHEMBL1128590 | 0.77 | GSK3B (0.55) | GSK3BQPCTPRKCAPRKCBKDR | |
| SCHEMBL4679888 | 0.77 | GSK3B (0.44) | GSK3BQPCTPRKCACDK4CCND1 | |
| SCHEMBL4682934 | 0.77 | GSK3B (0.44) | GSK3BQPCTPRKCA | |
| SCHEMBL4682941 | 0.76 | GSK3B (0.43) | GSK3BQPCTPRKCACDK4CCND1 | |
| SCHEMBL4680883 | 0.74 | GSK3B (0.63) | GSK3BQPCTPRKCAPRKCBKDR | |
| SCHEMBL13670446 | 0.74 | GSK3B (0.65) | GSK3BQPCTPRKCAPRKCBCCNE2 | |
| SCHEMBL1127687 | 0.74 | GSK3B (0.64) | GSK3BPRKCAPRKCBPRKCGPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| EP-1513520-B1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| US-20040054180-A1 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | PRKDC, MAP2K2, TTK | GSK3B 880/4885QPCT 2577/4885PRKCA 59/4885 |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | GSK3B 880/4885QPCT 2577/4885PRKCA 59/4885 |
| US-20040054180-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | GSK3B 880/4885QPCT 2577/4885PRKCA 59/4885 |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | GSK3B 880/4885QPCT 2577/4885PRKCA 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.